Composition for the prevention and treatment of osteoporosis containing dihydrophaseic acid 3'-O-beta-D-glucopyranoside isolated from Lycii Cortex extract

Osteoporosis treatment composition containing D3G compound derived from Lycii Cortex

This technology is a pharmaceutical composition for the prevention and treatment of osteoporosis that contains the dihydrophaseic acid D3G compound isolated from Lycii Cortex extract as an active ingredient.

Existing osteoporosis compositions often lacked clearly defined active ingredients, leading to low reproducibility of efficacy, and there were difficulties in identifying and isolating active compounds from Lycii Cortex.

By using the D3G compound isolated and purified from Lycii Cortex extract as an active ingredient, this technology can be applied to osteoporosis treatments and functional foods to prevent and treat the condition.

‍

‍

Key Features:

• A pharmaceutical composition containing dihydrophaseic acid D3G of Formula 1, isolated from Lycii Cortex extract, as an active ingredient
• A step of suspending Lycii Cortex extract in water and fractionating it with organic and aqueous solvents to obtain an aqueous fraction
• A step of obtaining primary sub-fractions from the aqueous fraction using open column chromatography with water and methanol
• A step of isolating and purifying the D3G compound from the primary sub-fractions using column chromatography

‍

This patent is owned by IPBank. Upon purchase, you may receive support through commercialization programs, recommendations for technology transfer and commercialization funding guarantees, and additional points during the evaluation for priority procurement of excellent inventions.

‍